{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:15:54Z","timestamp":1761110154174},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12094-015-1437-1","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T13:34:23Z","timestamp":1447940063000},"page":"1014-1019","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SEOM clinical guidelines for the treatment of follicular non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"17","author":[{"given":"M.","family":"Provencio Pulla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Alfaro Lizaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"de la Cruz Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gum\u00e1 i Padr\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Quero Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00f3mez Codina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Llanos Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Martinez Banaclocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rodriguez Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rueda Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019\u201332.","journal-title":"Blood"},{"key":"1437_CR2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE Project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"1437_CR3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12094-012-0813-3","volume":"14","author":"M Provencio","year":"2012","unstructured":"Provencio M, Sabin P, G\u00f3mez-Codina J, Rueda A, Llanos M, Gum\u00e1 J, et al. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol. 2012;14:386\u201390.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"1437_CR4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3324\/haematol.2010.034264","volume":"96","author":"R Marcos-Gragera","year":"2011","unstructured":"Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000\u20132002: results of the HAEMACARE project. Haematologica. 2011;96(5):720\u20138.","journal-title":"Haematologica"},{"key":"1437_CR5","unstructured":"Montes S, Mollejo M, Fraga M, Garc\u00eda JF, Villar JL, Mart\u00ednez A, et al. Recomendaciones para el estudio histopatol\u00f3gico, inmunohistoqu\u00edmico, citogen\u00e9tico y molecular e informe diagn\u00f3stico de los procesos neopl\u00e1sicos linfoides. Consenso SEAP-SEHH-GOTEL. 1a edici\u00f3n. Mayo 2015."},{"issue":"Supplement 3","key":"1437_CR6","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Supplement 3):iii76\u201382.","journal-title":"Ann Oncol"},{"key":"1437_CR7","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Stefan P, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"1437_CR8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowder D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convent to discuss the evaluation and staging of patients with Hodgkin\u2019s lymphoma: Cotswolds meeting. J Clin Oncol. 1989;7:1630\u20136.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1437_CR9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1437_CR10","first-page":"1258","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Dreyling M, White J, Armitage JO, Arranz-Saez R, et al. The follicular lymphoma prognostic index (FLIPI). Bood. 2004;104:1258\u201365.","journal-title":"Bood"},{"key":"1437_CR11","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for folicular lymphoma developed by the international folicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"1437_CR12","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning J. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1437_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4\u00a0Gy versus 24\u00a0Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457\u201363.","journal-title":"Lancet Oncol"},{"key":"1437_CR14","author":"DA Barzenje","year":"2015","unstructured":"Barzenje DA, Cvancarova Sm\u00e5stuen M, Liest\u00f8l K, Foss\u00e5 A, Delabie J, Kolstad A, et al. Ra diotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 Years. PLoS One. 2015. doi: 10.1371\/journal.pone.0131158:1-16 .","journal-title":"PLoS One"},{"key":"1437_CR15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, Nq A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64:928\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"1437_CR16","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848\u201353.","journal-title":"J Clin Oncol"},{"key":"1437_CR17","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368\u201375.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1437_CR18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","volume":"122","author":"GA Salles","year":"2013","unstructured":"Salles GA, Seymour JF, Feugier P, Offner F, LopezGuillermo A, Belada D, et al. Updated 6\u00a0year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood. 2013;122(21):509.","journal-title":"Blood"},{"issue":"9383","key":"1437_CR19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322.","journal-title":"Lancet"},{"key":"1437_CR20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506\u201313.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1437_CR21","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"I Flinn","year":"2014","unstructured":"Flinn I, van der Jagt R, Kahl RS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"key":"1437_CR22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"M Rummel","year":"2013","unstructured":"Rummel M, Niederle N, Maschmeyer G, Banat GA, won Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle- cell lymphoma: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"issue":"9759","key":"1437_CR23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet"},{"key":"1437_CR24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","volume":"101","author":"L Vidal","year":"2009","unstructured":"Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101:248\u201355.","journal-title":"J Natl Cancer Inst"},{"key":"1437_CR25","doi-asserted-by":"crossref","unstructured":"Provencio M, Cruz Mora M\u00c1, G\u00f3mez-Codina J, Quero Blanco C, Llanos M, Garc\u00eda-Arroyo FR, et al. Gotel (Spanish Lymphoma Oncology Group). Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leu Lymphoma. 2014;55(1):51\u20135.","DOI":"10.3109\/10428194.2013.790544"},{"issue":"7","key":"1437_CR26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, L\u00f3pez-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98(7):1014\u201321.","journal-title":"Haematologica"},{"issue":"4","key":"1437_CR27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","volume":"96","author":"MS Kaminski","year":"2000","unstructured":"Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259\u201366.","journal-title":"Blood"},{"issue":"21","key":"1437_CR28","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918\u201327.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-015-1437-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1437-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T15:43:09Z","timestamp":1599838989000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-015-1437-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s12094-015-1437-1","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]}}}